Hospital-Treated Gram-Negative Infections Market Size, Share, and Growth Forecast, 2026 - 2033

The global hospital-treated gram-negative infections market size is likely to be valued at US$11.8 billion in 2026, and is expected to reach US$22.6 billion by 2033, growing at a CAGR of 9.8% during the forecast period from 2026 to 2033, driven by the rising prevalence of multidrug-resistant gram-negative infections, increasing hospital-acquired infections, and the urgent need for effective antibiotics against resistant pathogens. The increasing incidence of carbapenem-resistant infections and demand for novel combination therapies remain major drivers of hospital-treated gram-negative infections market growth.

• Leading Region: North America, anticipated to account for a 38% market share in 2026, driven by rising antimicrobial resistance and increasing hospital-acquired gram-negative infections.
• Fastest-growing Region: Asia Pacific, fueled by rising hospital-acquired infections, improving diagnostic capabilities, and increasing antimicrobial resistance awareness in China and India.
• Dominant Therapy Type: Carbapenem, to hold approximately 34% of the market share, as it remains a critical last-resort treatment.
• Leading Pathogen Type: Klebsiella is expected to lead with ~30% market share in 2026, due to its high prevalence, resistance, and impact on serious hospital-acquired infections.

Driver - Rising Prevalence of Multidrug Resistant Gram Negative Infections

Antimicrobial resistance is making many common Gram negative bacterial infections significantly harder to treat in hospitals. According to the World Health Organization’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) data, about one in six laboratory confirmed bacterial infections globally were resistant to standard antibiotic treatments in 2023, reflecting a substantial rise in resistance patterns reported from over 100 countries. This trend is most pronounced among Gram negative pathogens such as Escherichia coli and Klebsiella pneumoniae in many regions, where over 40% of E. coli and more than 55% of K. pneumoniae isolates were resistant to third generation cephalosporins, the first line antibiotics typically used for serious infections like bloodstream infections and sepsis. In some parts of the world, particularly in Africa, resistance levels to these first choice drugs exceed 70%, drastically limiting effective treatment options and increasing reliance on later line, more toxic, or costlier antibiotics.

In the U.S., national surveillance highlights a similar upward trend in hard to treat Gram negative infections, especially those caused by carbapenem resistant organisms. Data from the Centers for Disease Control and Prevention (CDC) show that between 2019 and 2023, infections with highly resistant strains such as carbapenemase producing Enterobacterales, a group that includes some Gram negative “superbugs,” have surged, complicating clinical management and increasing hospital stays, healthcare costs, and patient mortality.

Growing Antimicrobial Resistance (AMR)

Antimicrobial resistance (AMR) has intensified into a major global public health issue, threatening the effectiveness of treatments once considered routine. According to the World Health Organization (WHO), AMR occurs when bacteria and other pathogens evolve mechanisms that reduce or nullify the efficacy of antimicrobial medicines, making infections harder to treat and increasing the risk of spread, severe disease, and death. Surveillance data from the WHO’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) show that as of 2023, AMR reporting encompasses 140 countries, territories, and areas, indicating both the global scope of the problem and governments’ efforts to track resistance patterns. This expanding surveillance highlights that resistant infections are not isolated but widespread across diverse healthcare settings and populations.

The human health impact of AMR is profound. In 2019, AMR was directly responsible for an estimated 1.27 million deaths worldwide and contributed to nearly 5 million deaths overall as resistant infections complicated treatment outcomes. These figures underscore how AMR has already eroded the effectiveness of essential antibiotics, with bacteria such as E. coli and Klebsiella pneumoniae showing high resistance levels to critical drugs like third generation cephalosporins.

Restraint - High Development and Treatment Costs

The development of new antibiotics and advanced therapies for treating hospital-acquired infections involves substantial financial investment, making cost a significant restraint on market growth. Creating effective drugs against multidrug-resistant gram-negative bacteria requires extensive research, long clinical trials, and regulatory approvals, all of which can take a decade or more and cost hundreds of millions of dollars. These high development costs are compounded by the limited commercial returns, as novel antibiotics are often reserved for severe or resistant cases to preserve their effectiveness, restricting widespread use.

For hospitals, the treatment itself is expensive due to the need for specialized drugs, prolonged hospital stays, and intensive care management for patients with severe infections. These financial burdens limit accessibility in low-resource settings and constrain hospital budgets, making institutions hesitant to adopt newer therapies.

Antimicrobial Resistance Pressure on Existing Drugs

The increasing resistance of bacteria to commonly used antibiotics significantly limits the effectiveness of existing treatments, creating a major challenge in managing hospital-acquired infections. Over time, pathogens such as Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa have developed mechanisms like enzyme production and efflux pumps that reduce drug efficacy, rendering standard therapies insufficient for severe infections.

This resistance not only complicates treatment protocols but also increases the likelihood of treatment failures, prolonged hospital stays, and higher morbidity and mortality rates. It also pressures healthcare providers to continuously monitor resistance patterns and adjust therapies, often with limited options.

Opportunity - Development of Innovative Antibiotics

The urgent need for effective treatments against multidrug-resistant gram-negative infections has spurred significant efforts in developing new antibiotics. Traditional antibiotics are increasingly losing their effectiveness due to widespread antimicrobial resistance, leaving clinicians with fewer therapeutic options for severe infections such as bloodstream infections, pneumonia, and complicated urinary tract infections. Innovative antibiotics aim to target resistant bacterial strains through novel mechanisms of action, such as inhibiting previously untargeted bacterial enzymes or disrupting essential bacterial processes. These drugs not only provide new treatment options but also help reduce reliance on existing antibiotics, slowing the further development of resistance.

In addition to new chemical entities, combination therapies that pair existing antibiotics with β-lactamase inhibitors are being explored to restore efficacy against resistant pathogens. Advances in biotechnology and genomics have also enabled precision approaches, allowing researchers to design antibiotics that target specific bacterial species while minimizing collateral damage to beneficial microbiota.

Advanced Rapid Diagnostic Technologies

Rapid and accurate diagnosis of infections is critical in combating multidrug-resistant gram-negative bacteria in hospital settings. traditional diagnostic methods, such as culture-based techniques, often take 24 to 72 hours to yield results, delaying the initiation of targeted therapy and increasing the risk of complications. Modern rapid diagnostic technologies, including polymerase chain reaction (PCR) assays, nucleic acid amplification tests (NAATs), and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, can identify pathogens and resistance genes within hours. These tools allow clinicians to quickly distinguish between bacterial species and detect resistance mechanisms, enabling timely and precise treatment decisions.

By reducing diagnostic turnaround time, rapid technologies help minimize the use of broad-spectrum antibiotics, which is essential for slowing the spread of antimicrobial resistance. They also improve patient outcomes by ensuring appropriate therapy is started earlier, reducing hospital stays and healthcare costs. Furthermore, these diagnostics support antimicrobial stewardship programs by providing data to monitor resistance trends and guide policy.

Therapy Type Insights

Carbapenem is anticipated to dominate, holding 34% share in 2026, supported by clinical practice guidelines that often prioritize carbapenems for severe, multidrug resistant infections where alternative antibiotics have failed or are not suitable, and by their widespread availability in hospital formularies. Despite rising resistance concerns, carbapenems remain critical in empiric and targeted treatment regimens, especially in ICUs where delayed effective therapy can significantly worsen patient outcomes. The hospital treated Gram negative infections market includes Shionogi & Co., Ltd., with its antibiotic cefiderocol (brand name FETROJA®), which has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of serious Gram negative bacterial infections. Initially, the FDA authorized cefiderocol for use in adults with complicated urinary tract infections (cUTIs) caused by susceptible Gram negative bacteria, particularly in cases where there are limited or no alternative treatment options available.

Ceftazidime/Avibactam represents the fastest-growing segment due to its potent activity against carbapenem-resistant organisms, including Klebsiella pneumoniae and Pseudomonas aeruginosa. By combining a third-generation cephalosporin (ceftazidime) with a novel β-lactamase inhibitor (avibactam), this therapy overcomes resistance mechanisms that render many antibiotics ineffective. Its ability to treat severe infections such as complicated urinary tract infections, intra-abdominal infections, and hospital-acquired pneumonia makes it a critical tool in intensive care and high-risk hospital settings. Avycaz®, a ceftazidime/avibactam antibiotic, is co-developed and marketed by AbbVie and Pfizer. The drug has received approval from the U.S. Food and Drug Administration (FDA), as well as other regulatory authorities, for treating serious infections caused by gram-negative bacteria. It is effective against pathogens such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa, particularly in cases where bacterial resistance restricts the use of standard antibiotic therapies.

Pathogen Type Insights

Klebsiella is anticipated to dominate, with nearly 30% of the market share in 2026, fueled by its high prevalence and significant resistance in healthcare settings. Hospitals prioritize treatments for these difficult-to-manage infections, as K. pneumoniae commonly causes serious nosocomial infections such as pneumonia, bloodstream infections, and urinary tract infections, especially in intensive care units or patients with invasive devices. Its growing resistance to multiple antibiotic classes, including last-resort drugs such as carbapenems, makes treatment challenging and costly. Klebsiella infections are effectively treated with Avycaz, an antibiotic developed collaboratively by AbbVie and Pfizer. This fixed dose combination has been approved by the U.S. Food and Drug Administration (FDA) for managing serious hospital-acquired infections, including hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), complicated intra-abdominal infections (cIAI) in combination with metronidazole, and complicated urinary tract infections (cUTI).

Acinetobacter represents the fastest-growing pathogen type, posing a significant threat in intensive care units (ICUs). Known for its ability to persist on surfaces for long periods, it can quickly develop resistance to multiple antibiotic classes, including carbapenems, complicating treatment. This pathogen frequently leads to ventilator-associated pneumonia, bloodstream infections, and wound infections in critically ill patients, making infection control and targeted therapy essential in hospital settings. Xacduro®, developed by Innoviva Specialty Therapeutics (a subsidiary of Innoviva, Inc.), has been approved by the U.S. Food and Drug Administration (FDA) for intravenous use in adults. It is indicated for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by the Acinetobacter baumannii calcoaceticus complex, a multidrug-resistant gram-negative pathogen that commonly affects critically ill patients in intensive care units (ICUs).

North America Hospital-Treated Gram-Negative Infections Market Trends

North America is projected to dominate, capturing 38% of revenue in 2026, powered by rising antimicrobial resistance, increasing hospitalization rates, and growing prevalence of multidrug-resistant gram-negative pathogens. Hospitals, particularly in the U.S. and Canada, are witnessing higher incidences of infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, often in intensive care units and among immunocompromised patients. The spread of carbapenem-resistant and extended-spectrum β-lactamase (ESBL) producing strains has amplified the need for advanced therapeutics, combination antibiotics, and targeted treatment strategies.

Technological advancements in rapid diagnostics, such as PCR-based tests and mass spectrometry, are enabling clinicians to identify pathogens and resistance patterns more quickly, allowing timely administration of appropriate therapy. Hospitals are increasingly adopting antimicrobial stewardship programs to optimize antibiotic usage, minimize resistance development, and improve patient outcomes. Government initiatives and infection-control protocols are being strengthened to reduce hospital-acquired infections. The demand for novel antibiotics, combination therapies, and improved diagnostic tools is rising, creating opportunities for pharmaceutical companies to introduce innovative solutions.

Europe Hospital-Treated Gram-Negative Infections Market Trends

The Europe market is increasingly influenced by the growing prevalence of multidrug-resistant pathogens and the continent’s strict regulatory frameworks for antimicrobial use. Countries such as Germany, France, and the U.K. report high incidences of carbapenem-resistant Enterobacteriaceae (CRE), particularly Klebsiella pneumoniae and Escherichia coli, which are associated with bloodstream infections, urinary tract infections, and hospital-acquired pneumonia. The rise of hospital outbreaks linked to resistant Acinetobacter baumannii has further stressed intensive care units, prompting hospitals to adopt rigorous infection-control measures, including patient isolation, environmental decontamination, and enhanced hand hygiene protocols.

European healthcare systems are also increasingly investing in rapid molecular diagnostics and genomic sequencing to detect resistance genes and guide precision antibiotic therapy. The implementation of EU-wide antimicrobial stewardship programs encourages rational prescribing, reducing unnecessary broad-spectrum antibiotic use and slowing resistance development. Telemedicine and electronic health records are being leveraged to monitor infection trends and optimize therapy at both hospital and regional levels.

Asia Pacific Hospital-Treated Gram-Negative Infections Market Trends

Asia Pacific is likely to be the fastest-growing region, propelled by high population density, increasing hospitalization rates, and the widespread prevalence of multidrug-resistant pathogens. Countries such as India, China, and Southeast Asian nations report rising incidences of infections caused by Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii, particularly in intensive care units and among immunocompromised patients. The region faces challenges from over-the-counter antibiotic availability and unregulated use in both human and veterinary medicine, which accelerates antimicrobial resistance and complicates infection management in hospitals.

Healthcare facilities in Asia Pacific are increasingly adopting rapid diagnostic technologies, including real-time PCR and automated microbial identification systems, to reduce diagnostic delays and guide targeted therapy. There is also a growing focus on infection prevention and control programs, such as hospital sanitation, sterilization protocols, and staff training, to curb nosocomial outbreaks. Governments are supporting local manufacturing of novel antibiotics and generic alternatives to improve accessibility and affordability. Telehealth integration is emerging as a tool for monitoring high-risk patients and ensuring timely intervention.

The global hospital-treated gram-negative infections market is highly competitive, with innovation and strategic development at the forefront of industry activity. Leading pharmaceutical companies, including Pfizer Inc., GSK plc, Merck & Co., Inc., AstraZeneca, Basilea Pharmaceutica Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Lupin, and Wockhardt Ltd., are investing heavily in research and development to create next-generation antibiotics and combination therapies targeting multidrug-resistant gram-negative pathogens. Competition is primarily driven by the ability of drugs to combat resistant strains, their safety and tolerability profiles, and inclusion in hospital formularies, which significantly impacts prescribing decisions.

To maintain a competitive edge, these companies are forming strategic partnerships, collaborations, and licensing agreements to accelerate the development of innovative treatments. They are also expanding hospital access programs to ensure the timely availability of critical antibiotics, particularly in intensive care and high-risk settings. Additionally, there is a growing emphasis on antimicrobial stewardship initiatives, where companies work closely with healthcare providers to optimize antibiotic use, minimize resistance development, and improve patient outcomes.

Key Industry Developments:

• In January 2025, Wockhardt Limited reported that its antibiotic Zaynich® (Zidebactam/Cefepime, WCK 5222) achieved over 97% clinical cure rates in patients with serious infections, including hospital-acquired pneumonia, ventilator-associated pneumonia, bloodstream infections, complicated urinary tract infections, and intra-abdominal infections. The study, conducted across 15 major hospitals in India, showed 100% efficacy in bloodstream infections, HABP/VABP, and intra-abdominal infections, with pathogen eradication rates exceeding 90%.